Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is slated to received unconditional EU antitrust approval for its proposed $16.5B acquisition of Catalent (CTLT), Reuters’ Foo Yun Chee and Maggie Fick report, citing a person with direct knowledge of the matter. Another source told Reuters that Catalent is preparing senior management for the takeover to go through.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue